BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30862611)

  • 1. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy.
    Famà R; Borroni E; Merlin S; Airoldi C; Pignani S; Cucci A; Corà D; Bruscaggin V; Scardellato S; Faletti S; Pelicci G; Pinotti M; Walker GE; Follenzi A
    Haematologica; 2021 Jun; 106(6):1624-1635. PubMed ID: 32467137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
    Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
    Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
    Kootstra NA; Matsumura R; Verma IM
    Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.
    Gong J; Yang R; Zhou M; Chang LJ
    Mol Med; 2023 Jun; 29(1):74. PubMed ID: 37308845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
    Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
    Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.